Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

BACKGROUND: Highly active antiretroviral therapy (HAART) was introduced in 1997. We aimed to assess the continuing effect of this treatment on survival and progression to AIDS after HIV-1 seroconversion. METHODS: We used Cox models to estimate the effect of calendar year on time to AIDS and death i...

Full description

Bibliographic Details
Main Authors:	Porter, K, Babiker, A, Bhaskaran, K, Darbyshire, J, Pezzotti, P, Walker, A
Format:	Journal article
Language:	English
Published:	2003

Similar Items

Age as a determinant of survival in HIV infection.
by: Babiker, A, et al.
Published: (2001)

Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion.
by: Thiébaut, R, et al.
Published: (2006)

Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
by: Babiker, A, et al.
Published: (2003)

Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE
by: Porter, K, et al.
Published: (2000)

Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors.
by: Bhaskaran, K, et al.
Published: (2004)

How soon after HIV seroconversion is antiretroviral therapy initiated?
by: Babiker, A, et al.
Published: (1999)

Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
by: Babiker, A, et al.
Published: (2002)

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
by: Touloumi, G, et al.
Published: (2008)

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
by: Smit, C, et al.
Published: (2006)

The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort.
by: Tyrer, F, et al.
Published: (2003)

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.
by: Touloumi, G, et al.
Published: (2004)

Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters.
by: Bhaskaran, K, et al.
Published: (2004)

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.
by: Fidler, S, et al.
Published: (2007)

Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
by: Gail V Matthews, et al.
Published: (2013-01-01)

Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion.
by: Del Amo, J, et al.
Published: (2003)

Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
by: Babiker, A, et al.
Published: (2000)

HIV/HCV coinfection, HAART, and liver-related mortality.
by: Sabin, C, et al.
Published: (2004)

Analysis of multivariate failure-time data from HIV clinical trials.
by: Walker, A, et al.
Published: (2000)

Overestimates of survival after HAART: implications for global scale-up efforts.
by: Gregory P Bisson, et al.
Published: (2008-03-01)

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion
by: Stirrup, O, et al.
Published: (2017)

Markers of HIV infection in the Concorde trial. Concorde Co-ordinating Committee.
by: Walker, A, et al.
Published: (1998)

Lipodystrophy syndrome in HIV-infected children on HAART
by: Steve Innes, et al.
Published: (2009-12-01)

HAART and ATT in the HIV-positive patient with tuberculosis
by: Zi Z Jhiens, et al.
Published: (2012-01-01)

A survival analysis of prognostic determinant factors of time-to-death of HIV/TB co-infected patients under HAART followed-up in a public hospital in Ethiopia
by: Delelegn Gebreyes
Published: (2022-12-01)

HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.
by: Sharon A Riddler, et al.
Published: (2017-01-01)

Fundus manifestations and HIV viral loads of AIDS patients before and after HAART
by: Yu Di, et al.
Published: (2019-09-01)

Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort
by: Van Santen, D, et al.
Published: (2019)

Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort
by: Tontodonati M, et al.
Published: (2014-12-01)

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
by: Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)
Published: (2001)

Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
by: Amengual MaJosé, et al.
Published: (2006-11-01)

Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study.
by: Niels Obel, et al.
Published: (2011-01-01)

Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells
by: Kloverpris, H, et al.
Published: (2012)

The impact of HIV-1 subtype on the clinical response on HAART.
by: Frater, J
Published: (2002)

Causes of hypercalcemia in people living with HIV in the HAART era
by: Arkom Nongnuch, et al.
Published: (2020-10-01)

Neurologic complications of HIV in the HAART era: where are we?
by: Monica M. Gomes da Silva

HIV seroconversion during pregnancy and the need for pre-exposure prophylaxis (PrEP)
by: Zorrilla CD, et al.
Published: (2018-04-01)

Gut dysbiosis and inflammatory blood markers precede HIV with limited changes after early seroconversion
by: Jennifer A. Fulcher, et al.
Published: (2022-10-01)

Penile bacteria associated with HIV seroconversion, inflammation, and immune cells
by: Jessica L. Prodger, et al.
Published: (2021-04-01)

Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil
by: Valeria Saraceni, et al.
Published: (2014-09-01)

Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
by: Leona Dold, et al.
Published: (2015-01-01)